Last reviewed · How we verify

NCT07083466

Assessment of Composite Inflammatory Ratios in Juvenile Idiopathic Arthritis and Their Association With Disease Activity

Not yet recruiting Last updated 24 July 2025
What this trial tests

trial testing complete blood count in Juvenile Idiopathic Arthritis in 90 participants. Not yet recruiting.

Timeline
15 July 2025
Primary endpoint
15 April 2026
15 April 2026

Quick facts

Lead sponsorSohag University
StatusNot yet recruiting
Study typeOBSERVATIONAL
Enrollment90
Start date15 July 2025
Primary completion15 April 2026
Estimated completion15 April 2026

Drugs / interventions tested

Conditions studied

Sponsor

Sohag University

Who can join

Under 16, any sex, with Juvenile Idiopathic Arthritis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Juvenile Idiopathic Arthritis (JIA) is a prevalent pediatric rheumatic disorder characterized by persistent inflammation of one or more joints in children and adolescents. This chronic condition is a major contributor to both short- and long-term morbidity and functional disability We aim in this study to investigate the role of CAR, PLR, NLR ,systemic inflammatory index (SII ) and NAR ( SII and NAR have never been evaluated before in JIA patients ) as potential markers of disease activity in patients with non-systemic JIA (nsJIA) .

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of complete blood count

Trials testing the same drug.

Other recruiting trials for Juvenile Idiopathic Arthritis

Currently open trials in the same condition.

Other Sohag University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07083466.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing